CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Mazyar Shadman, Piers Patten, Talha Munir et al.|Journal of Clinical Oncology|2024Cited by 8
CLL-769: Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): Post Hoc Analyses From the SEQUOIA StudyMazyar Shadman, Talha Munir, Constantine S. Tam et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1